Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data

Boggs, Jennifer
April 2010
BioWorld Today;4/28/2010, Vol. 21 Issue 81, p1
This article reports on the plan of Pluristem Therapeutics Inc. to conduct Phase II testing with its placenta-derived cell therapy treatment PLX-PAD in critical limb ischemia. The Israeli company announced the plan after reporting positive results from two Phase I trials of the treatment, including the absence of an immune response. Chairman and Chief Executive Officer (CEO) Zami Aberman noted the effectiveness of the drug in a number of cases.


Related Articles

  • PLURISTEM GETS INTERIM TOP-LINE RESULTS FROM PLX-PAD TRIALS.  // Worldwide Biotech;Jun2010, Vol. 22 Issue 6, p3 

    The article reports on the interim top-line results from the Phase I clinical trials of Pluristem Therapeutics Inc. in Haifa, Israel, in June 2010, which utilize the placenta-derived cell therapy product PLX-PAD for treating critical limb ischemia (CLI). The interim data showed that PLX-PAD is...

  • FDA Clinical Hold on PLX Safety Study Trips Pluristem. Powers, Marie // BioWorld Today;6/5/2013, Vol. 24 Issue 107, p1 

    The article reports on the 14.4% decrease in stocks of Pluristem Therapeutics Inc. amid the decision of the U.S. Food and Drug Administration (FDA) to stop the U.S. Phase II study of its Placental expanded cell therapy. Zami Aberman, chairman and chief executive officer of the biotechnology...

  • Will Cell-Based Therapy Shape Biopharma's Future?  // Contract Pharma;Jun2014, Vol. 16 Issue 5, p22 

    An interview with chief executive officer (CEO) Zami Aberman of biopharmaceutical company Pluristem is presented. Topics discussed by Aberman include the history of his stay at the company, the things needed to push stem cell injection technology to the next level, and the partners of the...

  • PLURISTEM COMPLETES DOSING FOR FIRST PATIENTS IN CLI TRIAL.  // Worldwide Biotech;Jan2010, Vol. 22 Issue 1, p6 

    The article reports on the completion by Pluristem Therapeutics Inc. of dosing of the first of three dosage groups of patients in Europe as part of its Phase I dose-escalating clinical trial of its placenta-derived cell therapy product PLX-PAD, for the treatment of critical limb ischemia (CLI)....

  • PLURISTEM GETS DSMB APPROVAL FOR PLX-PAD FINAL DOSE LEVEL.  // Biotech Business;Apr2010, Vol. 23 Issue 4, p6 

    The article announces the approval received by Pluristem Therapeutics Inc. of Haifa, Israel from the Safety Monitoring Board to advance to the highest and final dose level with its placenta-derived cell therapy (PLX-PAD) trial in Europe for the treatment of critical limb ischemia (CLI). Dr. Hans...

  • Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data. Boggs, Jennifer // BioWorld International;5/5/2010, Vol. 15 Issue 18, p5 

    The article deals with the preliminary Phase I data released by Pluristem Therapeutics Inc. for its placenta-derived cell therapy treatment PLX-PAD in critical limb ischemia in May 2010. Information on the Phase I trial results is presented. It discloses the company's negotiations for a Phase II...

  • Pluristem files IND application to begin Phase I critical limb ischemia trial.  // PharmaWatch: Biotechnology;Mar2009, Vol. 8 Issue 3, p10 

    The article reports on the investigational drug application filed by Pluristem Therapeutics to the U.S. Food and Drug Administration (FDA) in its aim to commence clinical trial with its placental-derived stromal cell product for the treatment of critical limb ischemia. The firm will begin its...

  • American Heart Association.  // BioWorld Today;11/17/2009, Vol. 20 Issue 222, p9 

    This article looks at the results of a Phase I/II trial by Aldagen Inc. for ALD-301, a cell therapy being developed for advanced critical limb ischemia. The study showed that ALD-301 was well tolerated. Also, patients treated with ALD-301 experienced an increase in blood flow and improvement in...

  • Cell Therapy Treatment for Critical Limb Ischemia. Prather, William R. // Drug Discovery & Development;Nov/Dec2009, Vol. 12 Issue 10, p40 

    The article discusses the treatment of the peripheral artery disease (PAD) critical limb ischemia (CLI) through cell therapy. It is stated that clinical trials are conducted by Pluristem Therapeutics Inc. in the U.S. and Europe to identify the effectiveness of adherent stromal cell (ASC) in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics